Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (28)

2024

  1. Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study

    Journal of Clinical Medicine, Vol. 13, Núm. 4

  2. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 1

2023

  1. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients

    Pharmaceutics, Vol. 15, Núm. 11

  2. Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 15

  3. Polymorphisms in VDR, CYP27B1, CYP2R1, GC and CYP24A1 Genes as Biomarkers of Survival in Non-Small Cell Lung Cancer: A Systematic Review

    Nutrients, Vol. 15, Núm. 6

2022

  1. Effect of Single Nucleotide Polymorphisms in the Vitamin D Metabolic Pathway on Susceptibility to Non-Small-Cell Lung Cancer

    Nutrients, Vol. 14, Núm. 21

2021

  1. Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis

    Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47

  2. Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives

    Mutation Research - Reviews in Mutation Research, Vol. 788

  3. Impact of Genetic Polymorphisms on the Metabolic Pathway of Vitamin D and Survival in Non-Small Cell Lung Cancer

    Nutrients, Vol. 13, Núm. 11

  4. Impact of a risk-sharing agreement in rheumatoid arthritis in Spain

    Health Policy, Vol. 125, Núm. 3, pp. 335-340

  5. Impact of genetic polymorphisms on the metabolic pathway of vitamin d and survival in non-small cell lung cancer

    Nutrients, Vol. 13, Núm. 11

  6. Influence of the fcgr2a rs1801274 and fcgr3a rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis

    Journal of Personalized Medicine, Vol. 11, Núm. 6

2020

  1. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta

    Mutation Research - Reviews in Mutation Research, Vol. 785

  2. Impact of single-nucleotide polymorphisms of CTLA-4, CD80 and CD86 on the effectiveness of abatacept in patients with rheumatoid arthritis

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-17

2015

  1. Differences in cancer drug assessment between Spain and the United Kingdom

    European Journal of Cancer, Vol. 51, Núm. 13, pp. 1843-1852

  2. Pharmaceutical care in smoking cessation

    Patient Preference and Adherence, Vol. 9, pp. 209-215

2014

  1. Drug assessment by a Pharmacy and Therapeutics committee: From drug selection criteria to use in clinical practice

    Therapeutics and Clinical Risk Management, Vol. 10, Núm. 1, pp. 527-535

  2. Implementing smart pump technology in a pediatric intensive care unit: A cost-effective approach

    International Journal of Medical Informatics, Vol. 83, Núm. 2, pp. 99-105

  3. Results of the implementation of a pharmaceutical care programme for patients with multiple sclerosis

    European Journal of Hospital Pharmacy, Vol. 21, Núm. 4, pp. 248-250

2013

  1. Effect of pharmacotherapy follow-up on treatment adherence and virologic and immune response in patients with human immunodeficiency virus

    Latin American Journal of Pharmacy, Vol. 32, Núm. 3, pp. 441-447